PA8596101A1 - USEFUL TRIAZOL COMPOUNDS IN THERAPY - Google Patents

USEFUL TRIAZOL COMPOUNDS IN THERAPY

Info

Publication number
PA8596101A1
PA8596101A1 PA20048596101A PA8596101A PA8596101A1 PA 8596101 A1 PA8596101 A1 PA 8596101A1 PA 20048596101 A PA20048596101 A PA 20048596101A PA 8596101 A PA8596101 A PA 8596101A PA 8596101 A1 PA8596101 A1 PA 8596101A1
Authority
PA
Panama
Prior art keywords
rent
ring
replaced
optionally
heterocicle
Prior art date
Application number
PA20048596101A
Other languages
Spanish (es)
Inventor
Justin Stephen Bryan
Patrick Stephen Johnson
Thomas Rickmans
Alan Stobie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8596101A1 publication Critical patent/PA8596101A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

UN COMPUESTO DE LA FORMULA (I) O UN DERIVADO DEL MISMO FARMACEUTICAMENTE ACEPTABLE, EN DONDE V REPRESENTA -(CH2)D(O)E-, -CO-O-CH(ALQUILO C1-6)-; W ES -O-,-S(O)A-O-N(R1)- R1 REPRESENTA H, ALQUILO C 1-6, (CH2)BCOR2, CO(CH2)BNR2R3, SO2R2, (CH)COR2, (CH2)CNR2R3 O (CH2)BHET1; HET REPRESENTA UN HETEROCICLO SATURADO O INSATURADO DE 3 A 8 ATOMOS, CONTENIENDO UNO O MAS HETEROATOMOS SELECCIONADOS ENTRE O,N, O S, OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-6; X Y Y REPRESENTAN INDEPENDIENEMENTE H, ALQUILO C1-6, HALOGENO, OH, CF3, OCF3, OR4; Z REPRESENTA -(CH2)F(O)G-, -CO- O -CH(ALQUILO C1-6)-; EL ANILLO A REPRESENTA UN HETEROCICLO SATURADO DE 4-7 MIEMBROS CONTENIENDO N, OPCIONALMENTE AL MENOS UN N DEL ANILLO ES SUSTITUIDO CON O; EL ANILLO B REPRESENTA FENILO O UN HETEROCICLO INSATURADO DE 4-7 MIEMBROS CONTENIENDO N, OPCIONALMENTE SUSTITUIDO CON OH, Y EN EL CUAL OPCIONALMENTE AL MENOS UN N DEL ANILLO ES SUSTITUIDO CON O; EL ANILLO B REPRESENTA FENILO O UN HETEROCICLO INSATURADO DE 4-7 MIEMBROS CONTENIENDO N, OPCIONALMENTE SUSTITUIDO CON OH, HALOGENO, CN, CONH2, CF3, OCF3, Y EN EL QUE OPCIONALMENTE AL MENOS UN N DEL ANILLO ESTA SUSTITUIDO CON O; R2 y R3 INDEPENDIENTEMENTE REPRESENTA H, ALQUILO C1-6 [OPCIONALMENTE SUSTITUIDO CON OH, HALOGENO, N(ALQUILO C1-6)2, O ALQUILOXI C1-6], N(ALQUILO C1-6)2 O [CICLOALQUILO C3-8]; O R2 y R3, JUNTOS CON EL ATOMO DE NITROGENO AL CUAL ELLOS ESTAN INDEPENDIENTEMENTE UNIDOS, REPRESENTAN UN HETEROCICLO DE ENTRE 3 A 8 ATOMOS, OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-6; R4 REPRESENTA UN ALQUILO C1-6 RAMIFICADO O DE CADENA RECTA, A Y C REPRESENTAN INDEPENDIENTEMENTE 0,1 O 2; B,E Y G REPRESENTAN INDEPENDIENTEMENTE 0 O 1; D Y F REPRESENTAN INDEPENDIENTEMENTE 1 O 2; SON UTILES EN EL TRATAMIENTO DE DISMENORREA.A COMPOUND OF FORMULA (I) OR A DERIVATIVE OF THE SAME PHARMACEUTICALLY ACCEPTABLE, WHERE V REPRESENTS - (CH2) D (O) E-, -CO-O-CH (C1-6 RENT) -; W ES -O -, - S (O) AON (R1) - R1 REPRESENTS H, RENT C 1-6, (CH2) BCOR2, CO (CH2) BNR2R3, SO2R2, (CH) COR2, (CH2) CNR2R3 O ( CH2) BHET1; HET REPRESENTS A SATURATED OR INSURED HETEROCICLE OF 3 TO 8 ATOMS, CONTAINING ONE OR MORE SELECTED HETEROATOMES BETWEEN OR, N, OR S, OPTIONALLY REPLACED WITH C1-6 RENT; X Y Y REPRESENT INDEPENDENTLY H, RENT C1-6, HALOGEN, OH, CF3, OCF3, OR4; Z REPRESENTS - (CH2) F (O) G-, -CO- OR -CH (C1-6 RENT) -; THE RING REPRESENTS A SATURATED HETEROCICLE OF 4-7 MEMBERS CONTAINING N, OPTIONALLY AT LEAST ONE N OF THE RING IS REPLACED WITH OR; RING B REPRESENTS PHENYLL OR AN INSURED HETEROCICLE OF 4-7 MEMBERS CONTAINING N, OPTIONALLY REPLACED WITH OH, AND IN WHICH OPTIONALLY AT LEAST ONE N OF THE RING IS REPLACED WITH OR; RING B REPRESENTS PHENYLL OR AN INSURED HETEROCICLE OF 4-7 MEMBERS CONTAINING N, OPTIONALLY REPLACED WITH OH, HALOGEN, CN, CONH2, CF3, OCF3, AND IN WHICH OPTIONALLY AT LEAST ONE N OF THE RING IS REPLACED WITH OR; R2 and R3 INDEPENDENTLY REPRESENTS H, C1-6 RENT [OPTIONALLY REPLACED WITH OH, HALOGEN, N (C1-6 RENTAL) 2, OR C1-6 RENT], N (C1-6 RENTAL) 2 OR [C3-8 CYCLEALKYL] ; OR R2 and R3, TOGETHER WITH THE NITROGEN ATOM TO WHICH THEY ARE INDEPENDENTLY UNITED, REPRESENT A HETEROCICLE BETWEEN 3 TO 8 ATOMS, OPTIONALLY REPLACED WITH C1-6 RENT; R4 REPRESENTS A C1-6 RAMIFIED OR STRAIGHT CHAIN RENT, A AND C REPRESENT INDEPENDENTLY 0.1 OR 2; B, E AND G REPRESENT INDEPENDENTLY 0 OR 1; D AND F REPRESENT INDEPENDENTLY 1 OR 2; They are useful in the treatment of dysmenorrhea.

PA20048596101A 2003-02-19 2004-02-18 USEFUL TRIAZOL COMPOUNDS IN THERAPY PA8596101A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0303852.8A GB0303852D0 (en) 2003-02-19 2003-02-19 Triazole compounds useful in therapy

Publications (1)

Publication Number Publication Date
PA8596101A1 true PA8596101A1 (en) 2005-08-04

Family

ID=9953327

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048596101A PA8596101A1 (en) 2003-02-19 2004-02-18 USEFUL TRIAZOL COMPOUNDS IN THERAPY

Country Status (11)

Country Link
CN (1) CN1751047A (en)
AR (1) AR043210A1 (en)
CL (1) CL2004000293A1 (en)
GB (1) GB0303852D0 (en)
GT (1) GT200400020A (en)
NL (1) NL1025527C2 (en)
PA (1) PA8596101A1 (en)
PE (1) PE20050222A1 (en)
TW (1) TW200500367A (en)
UY (1) UY28201A1 (en)
WO (1) WO2004074291A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325021D0 (en) * 2003-10-27 2003-12-03 Pfizer Ltd Therapeutic combinations
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
DE102004001871A1 (en) * 2004-01-14 2005-09-01 Bayer Healthcare Ag Tricyclic benzazepine derivatives and their use
JP2008510789A (en) * 2004-08-25 2008-04-10 ファイザー・インク Triazolobenzodiazepines and their use as vasopressin antagonists
WO2006114706A1 (en) * 2005-04-26 2006-11-02 Pfizer Limited Triazole derivatives as vasopressin antagonists
DK2356123T3 (en) 2008-11-13 2012-10-15 Hoffmann La Roche SPIRO-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo [e] azulenes
CN102216304B (en) * 2008-11-18 2014-07-09 弗·哈夫曼-拉罗切有限公司 Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
RU2507205C2 (en) 2008-11-28 2014-02-20 Ф. Хоффманн-Ля Рош Аг Arylcyclohexyl esters of dihydrotetraazabenzoazulenes for use as vasopressin v1a receptor antagonists
WO2010114894A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
AU2010317842A1 (en) * 2009-11-16 2012-07-12 Mellitech [1,5]-diazocin derivatives
US8420633B2 (en) * 2010-03-31 2013-04-16 Hoffmann-La Roche Inc. Aryl-cyclohexyl-tetraazabenzo[e]azulenes
US8461151B2 (en) * 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8492376B2 (en) * 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8481528B2 (en) * 2010-04-26 2013-07-09 Hoffmann-La Roche Inc. Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8513238B2 (en) * 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
US9006450B2 (en) * 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
SG188346A1 (en) 2010-10-07 2013-04-30 Takeda Pharmaceutical 1,4-oxazepane derivatives
RU2011122942A (en) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" NEW KINAZ INHIBITORS
US8828989B2 (en) * 2011-09-26 2014-09-09 Hoffmann-La Roche Inc. Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists
KR20140082765A (en) * 2011-10-05 2014-07-02 에프. 호프만-라 로슈 아게 Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists
RS55717B1 (en) 2012-06-13 2017-07-31 Hoffmann La Roche New diazaspirocycloalkane and azaspirocycloalkane
CN102766674A (en) * 2012-07-25 2012-11-07 辉源生物科技（上海）有限公司 Establishment of screening platform for cynomolgus monkey antidiuretic hormone receptor V1A antagonist
KR102179599B1 (en) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 New bicyclic derivatives
AR095079A1 (en) 2013-03-12 2015-09-16 Hoffmann La Roche DERIVATIVES OF OCTAHIDRO-PIRROLO [3,4-C] -PIRROL AND PIRIDINA-FENILO
PL3035939T3 (en) * 2013-08-19 2020-07-27 F. Hoffmann-La Roche Ag V1a antagonists to treat phase shift sleep disorders
KR20160087900A (en) 2013-11-26 2016-07-22 에프. 호프만-라 로슈 아게 New octahydro-cyclobuta [1,2-c ; 3,4-c']dipyrrol-2-yl
AU2014359409A1 (en) 2013-12-05 2016-05-19 F. Hoffmann-La Roche Ag Synthesis of trans-8-chloro-5-methyl-1 -[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof
EP3122750B1 (en) 2014-03-26 2019-09-04 F.Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
PE20161223A1 (en) 2014-03-26 2016-11-12 Hoffmann La Roche [1,4] DIAZEPINE CONDENSED COMPOUNDS AS INHIBITORS OF THE PRODUCTION OF AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA)
MA41898A (en) 2015-04-10 2018-02-13 Hoffmann La Roche BICYCLIC QUINAZOLINONE DERIVATIVES
RU2746481C1 (en) 2015-09-04 2021-04-14 Ф. Хоффманн-Ля Рош Аг Phenoxymethyl derivatives
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
PE20180451A1 (en) 2015-09-24 2018-03-05 Hoffmann La Roche NEW BICYCLE COMPOUNDS AS ATX INHIBITORS
WO2017050791A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
JP7090099B2 (en) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー A novel bicyclic compound as an ATX inhibitor
KR20190129924A (en) 2017-03-16 2019-11-20 에프. 호프만-라 로슈 아게 Heterocyclic Compounds Useful as Dual Autotaxin (ATX) / Carbon Anhydrase (CA) Inhibitors
WO2018226769A1 (en) * 2017-06-05 2018-12-13 Blackthorn Therapeutics, Inc. 1-(2-azaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives as v1a receptor antagonists for treating neuropsychological disorders
TW201938171A (en) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 Tricyclic compounds as vasopressin V1a receptor antagonists
HU231206B1 (en) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepines
CN111170983B (en) * 2019-12-26 2021-07-09 中国农业大学 Benzylthio acetamide compound and preparation method and application thereof
CN114644635B (en) * 2020-12-21 2023-02-03 上海济煜医药科技有限公司 Triazole tricyclic derivative and preparation method and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823475D0 (en) * 1988-10-06 1988-11-16 Merck Sharp & Dohme Chemical compounds
US5438035A (en) * 1994-06-24 1995-08-01 American Cyanamid Company Methods for controlling undesirable plant species with benzodiazepine compounds
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
DE69725182T2 (en) * 1996-11-01 2004-06-24 Wyeth 5H PYRROLO [2,1-c] [1,4] BENZODIAZEPINE-3-CARBOXAMIDE DERIVATIVES
IL144270A0 (en) * 1999-01-19 2002-05-23 Ortho Mcneil Pharm Inc Tricyclic benzodiazepines as vasopressin receptor antagonists
US7109193B2 (en) * 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists

Also Published As

Publication number Publication date
NL1025527A1 (en) 2004-08-23
GT200400020A (en) 2004-09-21
CL2004000293A1 (en) 2005-01-07
GB0303852D0 (en) 2003-03-26
AR043210A1 (en) 2005-07-20
UY28201A1 (en) 2004-09-30
TW200500367A (en) 2005-01-01
NL1025527C2 (en) 2005-03-14
PE20050222A1 (en) 2005-04-13
WO2004074291A1 (en) 2004-09-02
CN1751047A (en) 2006-03-22

Similar Documents

Publication Publication Date Title
PA8596101A1 (en) USEFUL TRIAZOL COMPOUNDS IN THERAPY
SV2005002099A (en) "NEW COMPOUNDS" REF. PC 32096A
PA8557401A1 (en) PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
CY1106679T1 (en) AZADICYCLIC HETEROCYCLIC COMPOUNDS AS CANNABINOID RECEPTOR MODIFIERS
ATE411317T1 (en) INDOLE-3-CARBINOL METABOLITES AS CHEMOTHERAPEUTIC AND CHEMOPREVENTIVE AGENTS
ECSP088431A (en) PIRAZOLO DERIVATIVES
DE602004014347D1 (en) CHINAZOLIN DERIVATIVES AS TGF BETA INHIBITORS
AR060159A2 (en) COMBINATIONS OF COMPOUNDS DERIVED FROM USEFUL TROPANE IN THERAPY
UY28693A1 (en) USEFUL COMPOUNDS IN THERAPY
DE60222775D1 (en) ANALOGUE AS ANTITUMORAL COMPOUNDS
MY137944A (en) Specific glucocorticoid compounds having anti-inflammatory activity
DE602006017715D1 (en) AZOL AND THIAZONE DERIVATIVES AND THEIR USE
ECSP055973A (en) USEFUL TRIAZOL COMPOUNDS IN THERAPY
UY28823A1 (en) ALPHA ARIL OR HETEROARIL METHYL BETA PIPERIDINE PROPANOIC ACID COMPOUNDS AS ANRL RECEIVER ANTAGONISTS
CO5690599A2 (en) DERIVATIVES OF 3- (4-AMINOFENIL) TIENOPIRIMID-4-ONA AS ANCHANGIST MCH R1 FOR THE TREATMENT OF OBESITY, DIABETES, DEPRESSION AND ANXIETY
PE20010634A1 (en) IMIDAZO-3-IL-AMINES BICYCLICAS, PROCEDURE FOR THEIR PREPARATION AND MEDICINES THAT CONTAIN THEM
DE602004023185D1 (en) PHENYLSULPHONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISEASES
CO5580722A2 (en) FUNGICIDE BLENDS
NO20072060L (en) 2 acylaminotiazolderivater
PA8563601A1 (en) ACIDS-3- (IMIDAZOLIL) -2- ALCOXIPROPANOICS
ES2073258T3 (en) NEW DERIVATIVES OF THE UREA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.
AR032358A1 (en) INHIBITING COMPOUNDS OF GLICINE TRANSPORTATION, PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
DOP2002000443A (en) PROCESS FOR QUINAZOLIN PRODUCTION
PA8563501A1 (en) ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS
ATE481408T1 (en) PURIFICATION OF BETA-LACTAM COMPOUNDS